TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of organoids successfully generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximal Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who initiate treatment over 1 year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who initiate treatment over 2 years
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Basal Metabolic Rate (BMR) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of surgeon-performed ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Normalized Muscle Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of Botox on crow's feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Confirmed overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Regional Homogeneity (ReHo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue adequacy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Rest in Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reach of the RISE program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the RISE program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success of implementation of the program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patterns of brain metabolites associated with neurotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline working memory at 10 days of intervention (scale assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline working memory at 10 days of intervention (computer-based assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline executive function at 10 days of intervention (scale assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline attention and executive function at 10 days of intervention (scale assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline processing speed at 10 days of intervention (scale assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Participants With Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Participants With ≥Grade 3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Participants With Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Neurocognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of laboratory parameters outside of normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of Clinician-Administrated PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol Response (Area Under the Curve) to CRH Under DEX Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mixed Muscle Fractional Synthesis Rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient relevant benefit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Retinal thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate to severe pain
Endpoint domain: Adverse events/effects
Primary endpoint: MWT sleep latency scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epworth Sleepiness Scale results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients to Mobilize ≥5 x 10^6 CD34 Cells/kg Autologous PBSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Achieved ≥5 x 10^6 CD34 Cells/kg in ≤4 Apheresis Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Participants Who Did Not Collect ≥5 x 10^6 CD34 Cells/kg in a Maximum of Four Apheresis Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blastocyst formation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: contractile function of the perineal musculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of each drug class
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in Finger to Floor Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Hernia recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of TH-302 in combination with doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of infarction lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: infarction location
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: size of subcortical lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: presence of multiterritorial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of blood pressure goal achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time interval from placement of Foley catheter to vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Drinks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rutgers Alcohol Problems Index (RAPI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the glucose over time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery of contractility in akinetic areas of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in left ventricular EF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade of Concordance between the CT and the 3D model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remaining volume of HA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target lesion failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nociceptive withdrawal reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement to estimate body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement to estimate heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement to estimate blood oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CD4+ T effector cells expressing IL-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite criteria of major and minor complications
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of the Oral contraceptive agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Poor Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bilateral ankle coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment - emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: blood level of pro-inflammatory cytokines TNFα and IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SLN detecting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in 6-minutes walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T CD8 lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy of POCUS and RADUS for intussusception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Adverse Events in the First 16 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Adverse Events After 16 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent adverse events (AEs) and serious AE (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ORR by Immune-related response criteria (irRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of new potential biomarkers of increased gastrointestinal cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants achieving specified dosimetric constraints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Risk of Medically Attended Events
Endpoint domain: Adverse events/effects
Primary endpoint: Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline fructosamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of duct volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 < 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of clot size removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Spontaneous abortion
Endpoint domain: Mortality/survival
Primary endpoint: Ectopic pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Caesarean section delivery
Endpoint domain: Mortality/survival
Primary endpoint: Change in Loneliness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Phenotypic and genotypic characterizations of movement disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of pulmonary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity of pulmonary blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity of visual perfusion deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity of airway wall metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity of emphysema quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity of air trapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of intraepithelial neoplasia grade 2/3 (CIN2/3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Accuracy in Attention and Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Reaction Time in Attention and Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Accuracy in Inhibition/Decision Making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Reaction Time in Inhibition/Decision Making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intensive care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ratio of the depth of the pre-epiglottic space to the distance from the epiglottis to the mid-point of the distance between the vocal cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior neck soft tissue thickness at the level of the vocal cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of regular medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine Transaminase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in physiological measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with adequate block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of anti-SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Altered composition of immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of serum Immunoglobulins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histologic Percentage of Vital Bone Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SLICC Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration-Time curve (AUC 2-10h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AR-V7 presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of AR-V7 in serum cfRNA assessed by quantitative RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to start of another treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative Morphine Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence With Treatment Per Night
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of AM PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Imagery vividness ratings
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skin conductance response (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in vulvar pain NRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CGMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total daily basal and bolus insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Successful First Attempt Lumbar Punctures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Epiphoric state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete absorption of subretinal fluid (SRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time to first administration of analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter-associated Venous Thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter-associated Bloodstream Infection
Endpoint domain: Adverse events/effects
Primary endpoint: serum concentration change in biomarker of endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum concentration change in biomarker of blood brain barrier disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum concentration change in biomarker of neuronal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The incidence of postoperative delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Bowel Wall Thickness (BWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Weighted Pediatric Crohn's Disease Activity Index (wPCDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone Fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematoma, urinary tract sepsis, or cardiac arrythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Upper Extremity Motor Score (UEMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spinal Cord Independence Measure (SCIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in size of wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in wound bed condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Participant Adherence to the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain caused by oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-t) for systemic exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for lung exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for systemic exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for lung exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tear Breakup Time Average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scores of the Ocular Surface Disease Index Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Decision Aid Education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Follow-up colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Food intake and nutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration time curve for primaquine and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in peripheral immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Existence of EGFR mutations in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of EGFR mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with EGFR mutation in peripheral blood and in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cellular immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of BP Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of BP Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of BP Study
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Imaging Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Imaging Study
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity assessed by CTCAE v3.0
Endpoint domain: Adverse events/effects